Literature DB >> 623430

Chemotherapy of human tumor xenografts in genetically athymic mice.

A A Ovejera, D P Houchens, A D Barker.   

Abstract

A series of studies were undertaken to evaluate the chemotherapeutic response to various antineoplastic drugs of human breast (MX-1) or colon (CX-2) tumor xenografts growing in genetically athymic (nude) mice. Fragments (2mm3) of either tumor type were implanted subcutaneously into the subaxillary region of NIH Swiss nude mice, and single drug therapy was started when tumors became palpable and were growing progressively. 5-Fluorouracil (5-FU) administered on a Q7DX3 schedule starting on Day 21 post tumor implantation elicited significant retardation in the growth rate of CX-2 tumor. A single treatment with methyl-CCNU induced temporary tumor regression. Against MX-1 tumor, both cyclophosphamide and melphalan induced tumor regressions with no recurrence. 5-FU slowed but did not arrest growth of MX-1 tumor. These tumor systems grown in nude mice appear to be suitable models for in vivo screening of anticancer agents that would prove clinically active.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 623430

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN: 0091-7370            Impact factor:   1.256


  46 in total

1.  Biological features and chemosensitivity of human colorectal cancer xenografted in nude mice.

Authors:  K Yamada
Journal:  Gastroenterol Jpn       Date:  1987-10

2.  Distinct morphological and immunohistochemical features and different growth rates among four human neuroblastomas heterotransplanted into nude mice.

Authors:  Nobuo Hoshi; Jiro Hitomi; Takashi Kusakabe; Takeaki Fukuda; Masayuki Hirota; Toshimitsu Suzuki
Journal:  Med Mol Morphol       Date:  2008-09-20       Impact factor: 2.309

3.  Microfluidic device for expedited tumor growth towards drug evaluation.

Authors:  Christopher George Uhl; Yaling Liu
Journal:  Lab Chip       Date:  2019-04-09       Impact factor: 6.799

4.  Three-dimensional culture of a mixed mullerian tumor of the ovary: expression of in vivo characteristics.

Authors:  T J Goodwin; T L Prewett; G F Spaulding; J L Becker
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997-05       Impact factor: 2.416

5.  Establishment of a transplantable carcinoma arising from the intrahepatic bile duct in Syrian golden hamsters.

Authors:  T Fukahori; T Tomioka; K Inoue; Y Tajima; T Tsunoda; T Kanematsu
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

6.  A standardized method of using nude mice for the in vivo screening of antitumor drugs for human tumors.

Authors:  M Imaizumi; T Kondo; T Taguchi; T Hattori; O Abe; M Kitano; A Wakui
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

7.  Growth, morphology, and serial transplantation of anaplastic human gliomas in athymic mice.

Authors:  S C Schold; D E Bullard; S H Bigner; T R Jones; D D Bigner
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

8.  In vivo selection of tumorigenic subline from non-tumorigenic human gastric carcinoma cells: in relation to proliferative properties in vivo and in nude mice.

Authors:  H Kubota; T Harada; S Morikawa; T Nakamura
Journal:  Gastroenterol Jpn       Date:  1988-08

9.  In vivo anti-tumor activity of photodynamic therapy with intravenous administration of acridine orange, followed by illumination with high-power flash wave light in a mouse osteosarcoma model.

Authors:  Haruhiko Satonaka; Katsuyuki Kusuzaki; Takao Matsubara; Ken Shintani; Tomoki Nakamura; Akihiko Matsumine; Takahiro Iino; Atsumasa Uchida
Journal:  Oncol Lett       Date:  2010-01-01       Impact factor: 2.967

10.  Comparison of alternate-day versus consecutive-day treatment with S-1: assessment of tumor growth inhibition and toxicity reduction in gastric cancer cell lines in vitro and in vivo.

Authors:  Wataru Arai; Yoshinori Hosoya; Hidenori Haruta; Kentaro Kurashina; Shin Saito; Yuuki Hirashima; Taku Yokoyama; Toru Zuiki; Kazuya Sakuma; Masanobu Hyodo; Yoshikazu Yasuda; Hideo Nagai; Tetsuhiko Shirasaka
Journal:  Int J Clin Oncol       Date:  2008-12-18       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.